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Abstract
A recent paper by Cameron et al. demonstrated that certain chemokines such as CCL19 activate cofilin and
actin dynamics, promoting HIV nuclear localization and integration into resting CD4 T cells. Apparently, these
chomokines synergize with the viral envelope protein, triggering cofilin and actin dynamics necessary for the
establishment of viral latency. This study opens a new avenue for understanding chemokine interaction with
HIV. Traditionally, chemokine control of HIV infection focuses on competitive binding and down-modulation of
the corecptors, particularly CCR5. This new study suggests that a diverse group of chemokines may also affect
HIV infection through synergistic or antagonistic interaction with the viral coreceptor signaling pathways.
Introduction
Despite the success of highly active antiretroviral therapy
(HAART) in inhibiting HIV replication, viral latency and
low-level replication permit viral persistence [1]. HIV can
be stably maintained in a variety of cells such as macro-
phages and resting CD4 T cells. In particular, the long-
lived, resting memory CD4 T cells have been shown to
be a major viral reservoir. Nevertheless, little is known
about the establishment of HIV latency in resting CD4 T
cells in the body. Previous studies have suggested that
HIV infection of resting CD4 T cells in vitro can lead to
viral DNA synthesis, although at a slower speed [2,3].
The virus is also capable of mediating nuclear migration
with the help of the viral envelope protein that triggers
signal transduction to promote cofilin and actin activities
[4,5]; viral DNA integration did not occur or was
observed at an extremely low level. Because non-inte-
grated viral DNA is not stable, the establishment of a
long-term reservoir in resting T cells requires stable inte-
gration that normally does not occur in the absence of
T cell activation or cytokine stimulation.
The lack of understanding of viral latency in resting
T cells has prompted a search for possible cellular con-
ditions that permit viral integration and latency. In
2007, Lewin’s group identified a novel mechanism of
HIV latent infection of resting CD4 T cells, in which
the CCR7 ligands, CCL19 and CCL21, were found to
drastically increase the permissiveness of resting CD4 T
cells to HIV infection [6]. Specifically, this enhancement
was attributed to CCL19/CCL21-mediated increases of
viral DNA nuclear migration and integration, but not
productive viral replication [6]. Recently, the same
group further demonstrated that the molecular mechan-
ism of the CCL19-CCR7 interaction shares similarity
with that of the HIV gp120-CXCR4 interaction in trig-
gering cofilin activation and actin dynamics which dras-
tically enhance viral nuclear migration and integration
[7]. Apparently, the CXCL19-mediated chemokine sig-
naling synergizes with the gp120-mediated activation of
cofilin through the chemokine receptors CCR7 and
CXCR4, respectively. Indeed, this appears to be consis-
tent with in vivo data showing that in HIV-infected
patients, enhanced levels of CCL19 and CCL21 correlate
with viral load, disease progression and patients’
response to HAART.
These findings open an avenue to examine the role of
chemokines in controlling HIV infection, and suggest a
potential new way of treating HIV infection. Traditionally,
chemokine control of HIV infection focuses on competi-
tive inhibition of viral entry through binding to the che-
mokine co-receptors, CCR5 in particular. This new result
suggests that HIV infection could also be affected with
chemokines interacting with multiple receptors such as
CCR7, CXCR3, or CCR6 [7] that may synergize or antago-
nize with HIV-mediated coreceptor signaling pathways.
Thus, a much broader range of surface receptors and
intracellular signaling molecules could be targeted.
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Chemokines are a group of small proteins with che-
moattractant properties, promoting leukocyte movement
through binding to G-protein-coupled chemokine recep-
tors (GPCR). Currently there are approximately 50 che-
mokines and 20 receptors identified (Figure 1). Among
them are the two main chemokine co-receptors of
HIV-1, CXCR4 and CCR5. Binding of chemokines to
their cognate GPCRs activates a diverse array of signal
pathways. Most of the signaling molecules are compo-
nents of the signaling transduction pathways mediating
chemotactic responses for cytoskeleton rearrangement,
cell polarization and migration, as well as transcriptional
activation, cell survival and proliferation [8]. Consistent
with the signaling diversity of the chemokine-receptor
interaction, binding of HIV-1 envelope (gp120) to CCR5
or CXCR4 has also been shown to trigger the activation
of multiple intracellular molecules such as cofilin that
increases the cortical actin dynamics to facilitate viral
nuclear migration [4,8].
I nar e c e n ts t u d yb yC a m e r o net al., the relationship
between HIV infection and multiple chemokines was
examined. Several key features emerged: (1) Certain che-
mokines such as CCL19, CXCL9/CXCL10, and CCL20
promote HIV nuclear migration and integration, whereas
others such as CCL1 and CCL13 do not. (2) There are
only limited changes in gene expression following che-
mokine exposure, suggesting that the enhancement on
HIV infection may not be at the gene expression level.
(3) The chemokine enhancement is not associated with
T cell activation, as no changes in surface expression of
CD69, HLA-DR, and CD25 were observed. (4) Chemo-
kine enhancement only occurs before or at the time of
HIV infection, and it is transit (as little as 3 h after treat-
ment) and reversible (lost if removed for more than 3 h),
which is consistent with the plasticity of cellular signal
transduction, and suggests that the enhancement likely
resulted from rapid changes in signaling pathways rather
than from breaking cellular restriction factors.
Although cofilin was identified in this study as the key
signaling molecule responsible for the CCL19-mediated
enhancement, for the chemokine system as a whole,
there are likely multiple mechanisms to affect HIV
infection, as chemokines are frequently pleiotropic. The
Cameron study also suggested possible new ways of
controlling HIV infection. Chemokines may be classified
into either “synergizer”, “antagonist”,o r“neutral” based
on their relationship with HIV infection. Treatment of
target cells with chemokine “synergizers” would enhance
HIV infection, whereas treatment with an “antagonist”
would do the opposite. “Neutral” chemokines may not
affect HIV infection in a significant manner.
Figure 1 Human chemokines and their receptors.
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(1) through inhibitors that target certain chemokine
receptors on the surface. These inhibitors may include
either inhibitory antibodies, small-molecule antagonists,
nonfunctional chemokines that bind but do not activate
viral-dependent pathways, or chemokine antagonists
that bind and transduce inhibitory signals for HIV repli-
cation; (2) through inhibitors that directly target the
intracellular chemokine signaling molecules such as
those regulating actin dynamics; (3) through inhibitors
that target the down stream effector molecules of che-
mokine signaling, mainly the cytoskeletal actin that is
involved in HIV entry, reverse trancription and nuclear
migration [4,9,10].
Conclusions
The recent transformative study by Cameron et al. calls
for an expansion of research scope on chemokine control
of HIV infection. It is imperative to initiate a systematical
investigation into the chemokine signaling network in
relation to HIV infection. This would pave the way for
future development of new classes of anti-HIV inhibitors
that could potentially act at multiple steps along the
chemokine signaling pathways.
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